Qualigen Corp (QLGN) - מקדם חוב לטווח ארוך להון

Qualigen Therapeutics seeks to restore physician confidence in its medical platforms. The price action on GURU.Markets, where the indicator stands at 0.00, accompanies a business based on the sale of FastPack systems and the development of anti-tumor drugs. The use of nanoparticles for intracellular drug delivery provides the company with patent advantages and the potential for premium pricing power within the viral pathology therapy sector.

This indicator determines the ratio of liabilities with a maturity of more than one year to the organization's equity. The metric measures the business's degree of dependence on debt financing over the long term. By analyzing the dynamics of the long-term debt-to-equity load, an investor assesses the stability of the balance sheet structure. For Qualigen Therapeutics (QLGN), this parameter is critical due to the capital-intensive transition toward drug development. The high risks associated with therapeutic programs make controlling the leverage a prerequisite for the company's survival.